 LOS ANGELES--BUSINESS WIRE--CytRx Corporation OTCQB:CYTR CytRx or the Company, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme AS NASDAQ:ORPH Orphazyme published the results from a Phase 23 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C NPC in the peer-reviewed Journal of Inherited Metabolic Disease JI 